ALS THERAPY DEVELOPMENT FOUNDATION INC

EIN: 043462719 501(c)(3) Medical Research

WATERTOWN, MA

Total Revenue
$13,406,171
Total Expenses
$12,879,065
Total Assets
$23,052,170
Net Assets
$18,634,048
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
1999
Legal Domicile
MA
Principal Officer
DR FERNANDO VIEIRA
Phone
6174417200
Tax Period
2024-01-01 to 2024-12-31

ALS THERAPY DEVELOPMENT FOUNDATION INC, founded in 1999, is a mid-sized nonprofit in the Medical Research sector that reported $13.4M in total revenue in fiscal year 2024. Revenue grew 16% year-over-year, indicating healthy expansion. Expenses of $12.9M left a modest 4% surplus.

Mission

WE ARE COMMITTED TO CREATING AND LEADING A TRANSPARENT COLLABORATIVE RESEARCH PROCESS THAT INVOLVES ALS PATIENTS TODAY AND HONORS THOSE WHOSE JOURNEY WITH THIS DISEASE HAS ENDED. WE ARE GUIDED BY PASSION, LOVE AND THE SPIRIT OF ENTREPRENEURSHIP UPON WHICH WE WERE FOUNDED.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $11,328,179
Program Service Revenue $1,312,529
Investment Income $465,979
Other Revenue $299,484
TOTAL REVENUE $13,406,171

Expense Breakdown

Grants Paid $0
Salaries & Benefits $5,595,580
Fundraising Expenses $620,667
Program Expenses $11,714,119
Other Expenses $7,256,610
TOTAL EXPENSES $12,879,065

Year-over-Year Comparison

2024 2023 Change
Revenue $13,406,171 $11,558,482 +0.2%
Expenses $12,879,065 $11,160,593 +0.2%
Net Income $527,106 $397,889 +0.3%
Key Indicators
✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
17
Independent Members
16
Employees
59
Volunteers
500

Governance Policies

✓ Conflict of Interest Policy
✓ Whistleblower Policy
✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School
✗ Operated a Hospital
✗ Provided First Class Travel
⚠ Reported Conflict of Interest
✗ Reported Asset Diversion
✗ Excess Benefit Transaction
✗ Made Political Expenditures
✗ Engaged in Lobbying
✗ Operated Donor Advised Fund
✗ Maintained Art Collections
✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
4
$414,933
Total Directors
18
$414,933
Key Employees
0
$0
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
FERNANDO VIEIRA CEO AND CSO 40.00
Officer Director
$386,901 $28,032 $414,933
LYNNE NIETO CHAIRMAN 2.50
Officer Director
$0 $0 $0
STEVEN PERRIN PHD VICE CHAIR 2.50
Officer Director
$0 $0 $0
THEODORE REICH JD CPA TREASURER AND BOARD MEMBER 2.50
Officer Director
$0 $0 $0
DR STANLEY H APPEL MD BOARD MEMBER 2.50
Director
$0 $0 $0
ALEXANDER CAPPELLO BOARD MEMBER 2.50
Director
$0 $0 $0
DR SPIROS JAMAS SCD BOARD MEMBER 2.50
Director
$0 $0 $0
JAMES ALLEN HEYWOOD BOARD MEMBER 2.50
Director
$0 $0 $0
JOHN B HEYWOOD PHD SCD BOARD MEMBER 2.50
Director
$0 $0 $0
ROB RODIN BOARD MEMBER 2.50
Director
$0 $0 $0
PAUL SALLABERRY BOARD MEMBER 2.50
Director
$0 $0 $0
ROBERT SEPUCHA BOARD MEMBER 2.50
Director
$0 $0 $0
JENNY DWYER BOARD MEMBER 2.50
Director
$0 $0 $0
MIKE SMITH BOARD MEMBER 2.50
Director
$0 $0 $0
JULIE SWAN BOARD MEMBER 2.50
Director
$0 $0 $0
KENT JACKSON BRANSFORD MD BOARD MEMBER 2.50
Director
$0 $0 $0
ANDREW NIBLOCK BOARD MEMBER (LEFT IN DEC 2024) 2.50
Director
$0 $0 $0
TOM ENGELLENNER BOARD MEMBER 2.50
Director
$0 $0 $0
ALAN GILL VP OF RESEARCH 40.00
Highest
$188,954 $19,776 $208,730
CAROL HAMILTON VP OF DEVELOPMENT 40.00
Highest
$172,628 $14,505 $187,133
THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 40.00
Highest
$155,581 $13,972 $169,553
KYLE R DENTON DIRECTOR, CELL BIOLOGY 40.00
Highest
$158,381 $26,707 $185,088
MEGHAN BUCO SENIOR DIRECTOR OF MARKETING & COMMUNICATIONS 40.00
Highest
$135,001 $20,819 $155,820
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 $13,406,171 $12,879,065 $23,052,170 $527,106
2023 $11,558,482 $11,160,593 $20,012,651 $397,889
2022 $11,364,169 $9,829,539 $21,051,525 $1,534,630
2021 $12,370,651 $8,987,486 $19,047,011 $3,383,165
2020 $10,248,613 $9,529,307 $29,996,989 $719,306
2019 $13,129,736 $11,458,890 $17,469,547 $1,670,846
2018 $15,038,596 $12,329,559 $15,652,260 $2,709,037
Explore More Nonprofits
→Top 100 Nonprofits in Massachusetts →Largest U.S. Nonprofits →Best Rated Nonprofits →Most Efficient Nonprofits

Compare ALS THERAPY DEVELOPMENT FOUNDATION INC with other nonprofits in Massachusetts and across the country.

We Value Your Privacy
We use cookies and similar technologies to analyze site traffic and improve your experience. By clicking "Accept All", you consent to our use of cookies for analytics and measurement.